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one member only had IgAN and one (or two relatives) tive treatments were very similar (i.e., 1.14 vs. 0.94 ng/mL/
had HSP. hour). Second, sodium intake was high and uncontrolled,
In our opinion, the possibility of such familial cases of allowing a lower baseline sodium excretion (intake)
IgAN and HSP can also be considered as another link before losartan treatment compared to placebo treat-
between the two diseases. ment ( sodium excretion 37 mEq/24 hours) and a higher
sodium excretion at the end of losartan treatment ( so-
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Therefore, the most plausible explanation for the
plasma renin data obtained by Agarwal [1] may be meth-REFERENCES
odological shortcomings and random fluctuations, but
1. David J-C, ten Berge IJ, Weening JJ: What is the difference be- no real effect of losartan. Parenthetically, this could
tween IgA nephropathy and Henoch-Scho¨nlein purpura nephritis?
also hold true for the results of glomerular filtrationKidney Int 59:823–834, 2001
2. Levy M, French Cooperative Group of the Society of Nephrol- rate (GFR) measurements, where GFR decreased (ran-
ogy: Familial cases of Berger’s disease and anaphylactoid purpura: domly) by 5 mL/min during placebo treatment (from 69
More frequent than previously thought. Am J Med 87:246–248, 1989
to 64 mL/min) and increased by 5 mL/min during losar-3. Levy M: Multiplex families in IgA nephropathy. Contrib Nephrol
104:46–53, 1993 tan treatment (from 63 to 68 mL/min) [1].
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expression severalfold from baseline [2]. Furthermore,
both 100 mg losartan and 80 mg quinalapril given for 10
days at this constant dose increased plasma renin activity
Reply from the author3- to 4-fold in 25 normotensive subjects on a controlled
I agree with Kra¨mer et al that the increase in plasma(low) sodium intake [3]. Finally, Stergiou et al recently
renin activity (PRA) with add-on losartan therapy wasdemonstrated that the addition of 80 mg valsartan for 5
unexpected [1]. However, I am unaware of any data inweeks to a maximal dose of chronic benazepril (20 mg
the population of patients that was studied to refute thosefor 6 weeks) significantly increased plasma renin activity
findings. Brown, Agirbasli, and Vaughan compared an-in 20 patients with primary hypertension [4].
giotensin-converting enzyme (ACE) inhibitors with an-The above results of Agarwal [1] may be explained by
giotensin II receptor blocker but did not study the combi-several shortcomings of this study. First, baseline plasma
nation in normotensive, sodium-restricted volunteers [2].renin activity before losartan treatment was 204% (!) of
In the study by Stergiou et al, benazepril was used in abaseline plasma renin activity before placebo treatment,
submaximal dose (20 mg/day) in patients with essentialwhereas plasma renin activities at the end of the respec-
hypertension [3]. In contrast, our patients received lisino-
pril for an average of 18 months in a dose of 40 mg/day
prior to participation in the trial. Such a dose is truly max- 2001 by the International Society of Nephrology
